Safety of Revaccination With Pneumococcal Polysaccharide Vaccine

Authors:
  • PBPatti Benson
    Patti Benson
  • VSVishnu-Priya Sneller
    Vishnu-Priya Sneller
  • JBJay C. Butler
    Jay C. Butler
  • RTRobert S. Thompson
    Robert S. Thompson
  • RCRobert T. Chen
    Robert T. Chen
  • LLLinda S. Lewis
    Linda S. Lewis
  • GCGeorge Carlone
    George Carlone
  • FDFrank DeStefano
    Frank DeStefano
  • PHPatricia Holder
    Patricia Holder
  • TLTamar Lezhava
    Tamar Lezhava
  • WWWalter W. Williams
    Walter W. Williams
Open Access
Publisher website
Google Scholar
Abstract
To prevent invasive pneumococcal disease, the Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) recommends vaccination with the 23-valent pneumococcal polysaccharide vaccine (PPV) for all persons aged 65 years or older and for younger persons with medical conditions that are associated with an increased risk of serious pneumococcal disease.1 Evidence that postvaccination antibody levels2-5 and protective efficacy6 may decline over time suggests that vaccine-induced protection may not be lifelong. Therefore, onetime revaccination after 5 or more years is recommended for 2 groups1: (1) persons aged 65 years or older vaccinated before the age of 65 years and (2) previously vaccinated persons aged 64 years or younger who are immunocompromised because of underlying medical conditions or medications.

This publication has 10 references indexed in Scilit: